Skip to main content

Articles By Eric Dein, MD

heel enthesitis spur calcaneal

How do you manage enthesitis?

16 February 2024

Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). It affects 27-35% of PsA patients and 36% of axSpA patients. Dr.

Read Article
RNL24

What are the Early Stages of Lupus?

14 February 2024

Incomplete lupus? Undifferentiated connective tissue disease? Pre-clinical autoimmune disease? During the lupus pod at RheumNow Live 2024, Dr. David Karp discussed the spectrum of autoimmune disease and the confusing terminology that is used with the complex world of early autoimmune disease. He cautioned against the traditional use of phrases such as incomplete lupus or undifferentiated connective tissue disease, which are heterogeneous and poorly defined.

Read Article
brain headache neuro

Best of 2023: Treatment and Management of Neuropsychiatric Lupus

29 December 2023

At the 2023 ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Best of 2023: Our old friend, hydroxychloroquine

18 December 2023

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Read Article
kidneys

ICYMI: Urinary biomarkers precede loss of kidney function for lupus nephritis

11 December 2023

In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.

Read Article
female with hands

ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?

07 December 2023

Should rheumatologists be counseling patients on cervical cancer prevention and screening?

Read Article
female with hands

Are Rheumatologists doing Enough for Cervical Cancer?

15 November 2023

Should rheumatologists be counseling patients on cervical cancer prevention and screening?

Read Article
kidneys

Urinary biomarkers precede loss of kidney function for lupus nephritis

14 November 2023

In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.

Read Article
syringe

IV Secukinumab for AxSpa

14 November 2023

The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

ICYMI: Our old friend, hydroxychloroquine

15 May 2023

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Read Article